Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter D Cole

Showing results (101-110 of 106) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 106 results.
The Lancet. Oncology|November 10, 2015
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trialAndrew E Place, Kristen E Stevenson, Lynda M Vrooman, et al.
Pediatric Blood & Cancer|October 7, 2020
Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001Melissa A Burns, Andrew E Place, Kristen E Stevenson, et al.
Pediatric Blood & Cancer|January 28, 2021
CorrigendumMelissa A Burns, Andrew E Place, Kristen E Stevenson, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patientsAndrew D J Pearson, Claudia Rossig, Giovanni Lesa, et al.
Journal of the National Cancer Institute|September 9, 2024
The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairmentMichelle C Janelsins, Kathleen Van Dyk, Sheri J Hartman, et al.
Cancer Discovery|February 10, 2021
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP ConsortiumYana Pikman, Sarah K Tasian, Maria Luisa Sulis, et al.
Pageof 11

Showing results (101-110 of 106) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 106 results.
The Lancet. Oncology|November 10, 2015
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trialAndrew E Place, Kristen E Stevenson, Lynda M Vrooman, et al.
Pediatric Blood & Cancer|October 7, 2020
Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001Melissa A Burns, Andrew E Place, Kristen E Stevenson, et al.
Pediatric Blood & Cancer|January 28, 2021
CorrigendumMelissa A Burns, Andrew E Place, Kristen E Stevenson, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patientsAndrew D J Pearson, Claudia Rossig, Giovanni Lesa, et al.
Journal of the National Cancer Institute|September 9, 2024
The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairmentMichelle C Janelsins, Kathleen Van Dyk, Sheri J Hartman, et al.
Cancer Discovery|February 10, 2021
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP ConsortiumYana Pikman, Sarah K Tasian, Maria Luisa Sulis, et al.
Pageof 11